Vedolizumab Efficacy, Safety and Pharmacokinetics with Reduced Frequency of Dosing from Every 4 to Every 8 Weeks in Patients with Ulcerative Colitis and Crohn's Disease

(1) University Hospitals Leuven,Leuven,Belgium

(2) Clinical Research Center for Inflammatory Bowel Diseases ISCARE,Prague,Czech Republic

(3) Centro Hospitalar Sao Joao,Porto,Portugal

(4) Takeda,Zurich,Switzerland

(5) Takeda,Cambridge,United States

(6) Humanitas University,Milan,Italy

This item was part of the Paradigm shifts in IBD treatment session at UEG Week 2019

This item can be cited as: United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019